Cargando…

Most adults with severe HbSC disease are not treated with hydroxyurea

Sickle cell hemoglobin SC (HbSC) disease is the second most frequent sickle cell disease (SCD) genotype after sickle cell anemia (HbSS). Globally, ∼55 000 newborns with HbSC are delivered annually, with the highest HbC gene frequency in West Africa. In Ghana, 40% of adults visiting the Ghana Institu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghunney, William Kwesi, Asare, Eugenia Vicky, Ayete-Nyampong, John Benaiah, Oppong, Samuel Antwi, Rodeghier, Mark, DeBaun, Michael R., Olayemi, Edeghonghon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Health Services and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362538/ https://www.ncbi.nlm.nih.gov/pubmed/36799926 http://dx.doi.org/10.1182/bloodadvances.2022009049

Ejemplares similares

Sustainability of low maternal mortality in pregnant women with SCD in a low-resource setting
por: Swarray-Deen, Alim, et al.
Publicado: (2022)

Epidemiology of Maternal Nutritional Status and Risk of Adverse Birth Outcomes in Undernourished Mothers with Sickle Cell Disease: A Systematic Review and Meta-Analysis Protocol
por: Klein, Lauren J., et al.
Publicado: (2023)

Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy
por: Cronin, Robert M., et al.
Publicado: (2022)

Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC)
por: da Guarda, Caroline Conceição, et al.
Publicado: (2020)

It’s high time to turn the spotlight on HbSC disease
por: Oluwole, Olubusola, et al.
Publicado: (2023)

Retinal thickness measurements in sickle cell patients with HbSS and HbSC genotype
por: Lim, Wei S., et al.
Publicado: (2018)

The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype)
por: Hannemann, A., et al.
Publicado: (2011)

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
por: Wang, Rong, et al.
Publicado: (2022)

HbSC Disease and Spontaneous Epidural Hematoma with Kernohan's Notch Phenomena
por: Yogarajah, Meera, et al.
Publicado: (2015)

Plasma levels of some coagulation parameters in Steady State HBSC disease patients
por: Ajuwon, Mauryne Debola, et al.
Publicado: (2014)

Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia
por: Lebensburger, Jeffrey D, et al.
Publicado: (2015)

Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC)
por: Brewin, John N., et al.
Publicado: (2020)

Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype)
por: Hannemann, A., et al.
Publicado: (2015)

Haemoglobin C Promotes Distinct Membrane Properties in Heterozygous HbSC red Cells
por: Clive Ellory, J.
Publicado: (2015)

Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic
por: DeBaun, Michael R.
Publicado: (2020)

2484: Establishment of the Tennessee-sickle cell disease network as a mechanism for engaging a rare disease population in patient centered outcomes research
por: Mayo-Gamble, Tilicia, et al.
Publicado: (2018)

Assessment of knowledge and quality of essential newborn care practices in La Dade Kotopon Municipality, Ghana
por: Ayete-Nyampong, John, et al.
Publicado: (2020)

Chronic Eosinophilic Leukemia Presenting as Cardiac Failure
por: Boi-Doku Pepra-Ameyaw, Nii, et al.
Publicado: (2022)

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

The pleiotropic effects of α‐thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co‐transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival
por: Brewin, John N., et al.
Publicado: (2022)

The “No bed syndrome” in Ghana — what, how and why? A literature, electronic and print media review
por: Yevoo, Linda Lucy, et al.
Publicado: (2023)

Improved Guideline Adherence With Integrated Sickle Cell Disease and Asthma Care
por: McClain, Brandi L., et al.
Publicado: (2016)

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020)

COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals
por: Singh, Ashima, et al.
Publicado: (2021)

Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
por: Hantel, Andrew, et al.
Publicado: (2021)

Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists
por: Stojkov, Igor, et al.
Publicado: (2021)

How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines
por: Nieuwlaat, Robby, et al.
Publicado: (2021)

The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States
por: Sacks, Naomi C., et al.
Publicado: (2022)

Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes
por: LoCastro, Marissa, et al.
Publicado: (2021)

Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
por: Kuczmarski, Thomas M., et al.
Publicado: (2022)

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology
por: Wood, William A., et al.
Publicado: (2021)

Code status transitions in patients with high-risk acute myeloid leukemia
por: Abrams, Hannah R., et al.
Publicado: (2022)

Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
por: Johnson, Kate M., et al.
Publicado: (2022)

Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
por: Chien, Kelly S., et al.
Publicado: (2023)

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis
por: Luan, Danny, et al.
Publicado: (2022)

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
por: O’Donnell, Elizabeth K., et al.
Publicado: (2022)

Coping in caregivers of patients with hematologic malignancies undergoing hematopoietic stem cell transplantation
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

What do patients think about palliative care? A national survey of hematopoietic stem cell transplant recipients
por: Barata, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ag2splkq2kmhch8uqqbm1jj4j